ClinicalTrials.gg

Program

puxitatug samrotecan

Also written as “AZD8205”, “AZD8205 in combination with AZD9574” and “Puxitatug Samrotecan”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms, led by AstraZeneca.

Furthest: phase 3, since Jun 23, 20252 company-led studies, 2 open or runningNext primary completion: Sep 29, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 3since Jun 23, 2025Oct 13, 2021Sep 29, 2027phase 2 · NCT05123482
  • Named in AstraZeneca’s own pipeline as puxitatug samrotecan, phase 3, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2021First study: phase 2 study in Breast NeoplasmsFirst studyNCT05123482 · 460 planned · United States, Australia, Belgium and more
  2. Jun 23, 2025Phase 3 study in Endometrial NeoplasmsNCT07044336 · 800 planned · United States, Argentina, Australia and more

Ahead

  1. Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
  2. Oct 15, 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT07044336

TargetBeta

“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to samrotecan, which is coposed of a linker and the topoisomerase-1 inhibitor (TOP1i; TOP-Ii) exatecan, with potential antineo…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule

Other programs on VTCN1

ProgramCompanyFurthest phaseStudies
mocertatug rezetecanGlaxoSmithKlinephase 311
Anti-B7-H4 Antibody Drug Conjugate BG-C9074ruleBeOne Medicinesphase 32
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-B7-H4/MMAE ADC LNCB74ruleligachem-biosciences-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07044336Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingOct 15, 2027800
NCT05123482Breast Neoplasms · United States, Australia, Belgium and more2RecruitingSep 29, 2027460

How it is read

Names in the registry

  • “AZD8205”, 1 entry
  • “AZD8205 in combination with AZD9574”, 1 entry
  • “Puxitatug Samrotecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.